Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of
A variety of benzofurans and indole derivatives some with an alkynyl linker are disclosed herein. These compounds are not highly charged at physiological pH and have good bioavailability characteristics. These compounds exhibit selective or at least preferential affinity for the active sites of various sub-sets of protein tyrosine phosphatases. Some of these compounds are excellent inhibitors of Mycobacterium protein tyrosine phosphatase B (mPTPB) a protein tyrosine phosphatase expressed in Mycobacterium tuberculosis and characterized as a virulence factor in the causal agent of tuberculosis. Accordingly, many of these compounds and pharmaceutically acceptable salts thereof are useful for the treatment of diseases such as tuberculosis.
1. A compound of Formula A, or a pharmaceutically acceptable salt thereof,
wherein X is O or NR 2 ;
R 1 is selected from the group consisting of:
and each occurrence of R 2 can be the same or different and is H or C 1 -C 6 alkyl; each occurrence of R 3 can be the same or different and is H, halogen, hydroxyl, NR 2 R 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 alkenyl, substituted or unsubstituted C 1 -C 6 alkynyl, O-(substituted or unsubstituted C 1 -C 6 alkyl), S-(substituted or unsubstituted C 1 -C 6 alkyl), O-(substituted or unsubstituted aryl), O-(substituted or unsubstituted heteroaryl), S-(substituted or unsubstituted aryl), S-(substituted or unsubstituted heteroaryl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, SO 2 -(substituted or unsubstituted C 1 -C 6 alkyl), SO 2 NR 2 R 2 , C(O)-(substituted or unsubstituted C 1 -C 6 alkyl), C(O)-(substituted or unsubstituted aryl), C(O)-(substituted or unsubstituted heteroaryl), (CH 2 ) n CO 2 H, or O(CH 2 ) n CO 2 H;
Y is H, halogen, hydroxyl, NR 2 R 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 alkenyl, substituted or unsubstituted C 1 -C 6 alkynyl, O-(substituted or unsubstituted C 1 -C 6 alkyl), S-(substituted or unsubstituted C 1 -C 6 alkyl), O-(substituted or unsubstituted aryl), O-(substituted or unsubstituted heteroaryl), S-(substituted or unsubstituted aryl), S-(substituted or unsubstituted heteroaryl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, SO 2 C 1 -C 6 alkyl, SO 2 NR 2 R 2 , C(O)-(substituted or unsubstituted C 1 -C 6 alkyl), C(O)-(substituted or unsubstituted aryl), C(O)-(substituted or unsubstituted heteroaryl); —(CH 2 ) n COZ, or —O—(CH 2 )n-COZ;
n can be the same or different at each occurrence and is 1, 2, 3, or 4;
Z is —OH, or N(R 4 ) 2 , wherein each occurrence of R 4 can be the same or different and is H, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 1 -C 6 alkenyl, substituted C 1 -C 6 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, OR 5 , NHR 5 ,
and
R 5 is substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C(O)-(substituted or unsubstituted C 1 -C 6 alkyl), C(O)-(substituted or unsubstituted aryl), C(O)-(substituted or unsubstituted heteroaryl), or C(O)-(substituted or unsubstituted C 3 -C 8 cycloalkyl).
2. A compound of claim 1 , wherein Y is H, halogen, hydroxyl, NR 2 R 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 alkenyl, substituted or unsubstituted C 1 -C 6 alkynyl, O-(substituted or unsubstituted C 1 -C 6 alkyl), S-(substituted or unsubstituted C 1 -C 6 alkyl), O-(substituted or unsubstituted aryl), O-(substituted or unsubstituted heteroaryl), S-(substituted or unsubstituted aryl), S-(substituted or unsubstituted heteroaryl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, SO 2 C 1 -C 6 alkyl, SO 2 NR 2 R 2 , C(O)-(substituted or unsubstituted C 1 -C 6 alkyl), C(O)-(substituted or unsubstituted aryl), or C(O)-(substituted or unsubstituted heteroaryl).
3. The compound of claim 2 , wherein X is O.
4. The compound of claim 2 , wherein X is NR 2 .
5. The compound of claim 3 , wherein R 1 is
6. The compound of claim 4 , wherein R 1 is
7. The compound of claim 5 , wherein each occurrence of R 3 can be the same or different and is H, Cl, F, OCH 3 , CF 3 , OCF 3 , OPh, or OCH 2 CO 2 H, and Y is H, CF 3 , OCF 3 , Cl, Ph, or OPh.
8. The compound of claim 6 , wherein each occurrence of R 3 can be the same or different and is H, Cl, F, OCH 3 , CF 3 , OCF 3 , OPh, or OCH 2 CO 2 H, and Y is H, CF 3 ,OCF 3 , Cl, Ph, or OPh.
9. The compound of claim 4 , wherein R 1 is hydrogen.
10. The compound of claim 3 , wherein Y is H, Ph, Cl, OCF 3 , or OPh.
11. The compound of claim 9 , wherein Y is H, Ph, Cl, OCF 3 , or OPh.
12. A compound of Formula C, or a pharmaceutically acceptable salt thereof,
wherein D is O or NR 8 ;
R 8 is H or C 1 -C 6 alkyl;
E is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted C 3 -C 8 cycloalkyl; and
G is C(O)-(substituted or unsubstituted C 1 -C 6 alkyl), C(O)-(substituted or unsubstituted C 3 -C 8 cycloalkyl), C(O)-(substituted or unsubstituted C 1 -C 6 alkenyl), C(O)-(substituted or unsubstituted C 1 -C 6 alkynyl), C(O)-(substituted or unsubstituted aryl), or C(O)-(substituted or unsubstituted heteroaryl).
13. The compound of claim 12 , wherein D is O.
14. The compound of claim 12 , wherein D is NR 8 .
15. The compound of claim 13 , wherein E is cyclohexyl or
R 9 is H, Ph, F, CF 3 , OCF 3 , or OH, and G is selected from the group consisting of:
16. The compound of claim 12 , wherein E is cyclohexyl or
R 9 is H, Ph, F, CF 3 , OCF 3 , or OH, NR 8 is CH 3 ; and G is selected from the group consisting of:
17. A method of treating a patient, comprising the step of:
administering to an individual in need thereof a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof to a patient, where the patient has at least one disease, disorder, or condition associated with pathological activity of a protein tyrosine phosphatase wherein said disease, disorder, or condition is tuberculosis.